For the past 20 years, Vanderbilt Health researchers have been studying ifetroban for its potential to treat conditions ranging from fibrotic lung disease to heart failure in patients with Duchenne muscular dystrophy.

Genetic variants known to slow or speed metabolism of drugs for depression and anxiety disorders are very common.

With the addition of the J-Valve device, Vanderbilt Health now offers minimally invasive procedures to implant devices treating every valve disease. The trial is still enrolling new patients, so other high-risk patients with aortic regurgitation could qualify.

This minimally invasive and cost-effective alternative to tissue biopsy offers “an accessible tool for tailoring treatment strategies in breast cancer,” researchers reported April 22 in the journal Science Translational Medicine.

An estimated 200,000 people in the United States have lupus. About 80% of them experience “brain fog,” cognitive problems that impair learning, memory and attention. The EG501 study was the inaugural project of Vanderbilt Health’s Drug Repurposing program.

Gram-negative bacteria bloodstream infections are a major cause of illness and death worldwide, especially where antimicrobial resistance is more common.  

Vanderbilt Health’s Firefly program continues to lead the way in caring for pregnant women with substance use disorder.